Repurposing Montelukast for Cardiac Surgery-Associated Acute Kidney Injury
重新利用孟鲁司特治疗心脏手术相关的急性肾损伤
基本信息
- 批准号:10043764
- 负责人:
- 金额:$ 38.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAdultAffectAlgorithmsAllergic rhinitisAnimal ModelAnti-Inflammatory AgentsArachidonic AcidsArrhythmiaAsthmaBindingBudgetsCardiac Surgery proceduresCaringCase Report FormCessation of lifeCharacteristicsChronic Kidney FailureClinicalClinical ProtocolsClinical TrialsClinical trial protocol documentCodeCohort StudiesCommunitiesComplicationConsent FormsContractsDNADataDeteriorationDevelopmentDiagnosisDialysis procedureDiseaseDoseElectronic Health RecordEligibility DeterminationEnd stage renal failureEnrollmentEventExclusion CriteriaFDA approvedFunctional disorderGeneric DrugsGenesGenotypeGoalsInflammationInflammatoryInformed ConsentInfrastructureInjury to KidneyIntensive Care UnitsKidney DiseasesLanguageLeukotriene AntagonistsLeukotriene C4Leukotriene D4Leukotriene E4Leukotriene ReceptorLeukotrienesMeasuresMedicalMethodsMonitorNephritisOperative Surgical ProceduresOutcomePatient Outcomes AssessmentsPatient RecruitmentsPatient RepresentativePatientsPerioperativePharmaceutical PreparationsPharmacologyPhenotypePhysiciansPostoperative PeriodPre-Clinical ModelPrevalencePreventionProceduresProteinsPublishingRecoveryRegimenRenal functionResearch DesignRiskRisk FactorsSafetySample SizeScientistSecureSepsisSingle Nucleotide PolymorphismSiteSocietiesSpecimenStatistical Data InterpretationSystemTechniquesTestingTimeTreatment EfficacyUnited StatesUrineWound Infectionbasebiobankcohortdesigndisease phenotypeexperiencehuman dataimprovedmontelukastmortalitymultidisciplinarynew therapeutic targetnovelnovel therapeuticspatient populationphase II trialphenomepreventprimary endpointprogramsrecruitsecondary endpointshared databasetoolurinary
项目摘要
PROJECT SUMMARY/ABSTRACT
Each year 500,000 patients undergo cardiac surgery in the United States, and acute kidney injury (AKI)
complicates recovery in 25% of patients. AKI is associated with subsequent postoperative arrhythmias, wound
infections, and sepsis, and independently predicts a 5-fold increase in death at 30 days. Despite advancements
in surgical technique and perioperative patient management, cardiac surgery-associated AKI (CSA-AKI) remains
a major problem and no therapies have been shown to improve clinical outcomes. While there are many reasons
that previous efforts to identify and validate new therapeutic targets for AKI have been unsuccessful, a key
feature is that discovery efforts were not primarily driven by human data. Leveraging BioVU (Vanderbilt's large-
scale DNA biobank), we performed a Phenome-Wide Association Study (PheWAS) based on ICD billing code
and genotype data in a disease-agnostic cohort of ~36,000 patients and identified novel genotype-phenotype
associations between single nucleotide polymorphisms in the gene that encodes the protein target of
montelukast (CYSTLR1) and AKI phenotypes. Montelukast is an anti-inflammatory leukotriene receptor
antagonist that is FDA approved to treat asthma and allergic rhinitis, and inflammation is a mechanism of AKI.
In additional preliminary studies montelukast reduces renal injury in preclinical models, urinary concentrations of
leukotrienes increase significantly during cardiac surgery and more so in patients who develop AKI, and patients
taking montelukast have a 38% reduction in AKI over time compared to patients not taking montelukast.
To determine if montelukast can be repurposed to prevent CSA-AKI and potentially other forms of AKI in
subsequent initiatives, we will first perform a phase II trial to measure the effect of montelukast on CSA-AKI and
assess any safety events. To properly design and execute this phase II trial we assembled a multidisciplinary
team of physician scientists and staff with the relevant expertise and experience to accomplish four specific aims:
(1) Determine study cohort availability and baseline characteristics by simulating study cohorts using VUMC's
Synthetic Derivative; (2) Determine optimal montelukast dosing regimen and refine the trial's mechanistic studies
by measuring LTC4, LTD4, and LTE4 leukotriene subtypes in urine of patients who did and did not develop AKI
in a previous study; (3) Optimize study design to most efficiently recruit patients and test the hypothesis; and (4)
Complete all study startup tasks. The successful completion of this project will allow us to commence the clinical
trial immediately. Proving that a safe, affordable, generic drug can be used to prevent CSA-AKI is a major priority.
In addition, demonstration that the published and publicly available computational PheWAS algorithm is an
effective tool for drug repurposing will lead to additional medical treatments.
项目摘要/摘要
在美国,每年有50万患者接受心脏手术和急性肾损伤(AKI)
在25%的患者中使康复变得复杂。AKI与随后的术后心律失常、伤口
感染和败血症,并独立预测30天内死亡人数增加5倍。尽管取得了进步
在外科技术和围手术期患者管理方面,心脏手术相关AKI(CSA-AKI)仍然存在
这是一个主要的问题,而且没有任何治疗方法被证明可以改善临床结果。虽然有很多原因
之前确定和验证AKI新治疗靶点的努力都没有成功,这是一个关键
特点是,发现工作主要不是由人类数据驱动的。利用BioVU(Vanderbilt的大型-
Scale DNA Biobbank),我们基于ICD计费代码进行了一项表现组范围关联研究(Phewas
在一个约36,000名患者的疾病不可知队列中的基因和基因数据,并确定了新的基因-表型
编码蛋白靶标基因的单核苷酸多态之间的关联
孟鲁司特(CystLR1)和AKI表型。孟鲁司特是一种抗炎白三烯受体
FDA批准用于治疗哮喘和过敏性鼻炎的拮抗剂,炎症是AKI的一个机制。
在其他的初步研究中,孟鲁司特可减少临床前模型中的肾损伤,尿药浓度
白三烯在心脏手术期间显著增加,在发生AKI的患者和患者中更是如此
服用孟鲁司特的患者与不服用孟鲁司特的患者相比,随着时间的推移,AKI减少了38%。
确定孟鲁司特是否可以改变用途以预防CsA-AKI和潜在的其他形式的AKI
随后,我们将首先进行第二阶段试验,以衡量孟鲁司特对CsA-AKI和
评估任何安全事件。为了恰当地设计和执行这项II期试验,我们组建了一个多学科的
由具有相关专业知识和经验的内科医生、科学家和工作人员组成的团队,以实现四个具体目标:
(1)通过使用VUMC的模拟研究队列来确定研究队列可用性和基线特征
(2)确定孟鲁司特的最佳给药方案,完善试验的机理研究
检测AKI患者尿液中LTC4、LTD4和LTE4白三烯亚型
在之前的研究中;(3)优化研究设计,以最有效地招募患者并检验假设;以及(4)
完成所有研究启动任务。该项目的成功完成将使我们能够开始临床
立即开庭审理。证明一种安全、负担得起的仿制药可以用于预防CsA-AKI是一个主要的优先事项。
此外,还证明了公开发布的计算Phewas算法是一种
有效的药物再利用工具将带来额外的医疗治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Frederic Tremaine Billings其他文献
Frederic Tremaine Billings的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Frederic Tremaine Billings', 18)}}的其他基金
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
减少围术期氧化应激以预防全膝关节置换术后慢性疼痛
- 批准号:
10793361 - 财政年份:2023
- 资助金额:
$ 38.91万 - 项目类别:
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
- 批准号:
9113044 - 财政年份:2015
- 资助金额:
$ 38.91万 - 项目类别:
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
- 批准号:
9253963 - 财政年份:2015
- 资助金额:
$ 38.91万 - 项目类别:
Hyper-oxygenation, oxidative stress, and kidney injury following cardiac surgery
心脏手术后的高氧合、氧化应激和肾损伤
- 批准号:
8801217 - 财政年份:2015
- 资助金额:
$ 38.91万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
8885846 - 财政年份:2012
- 资助金额:
$ 38.91万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
8520356 - 财政年份:2012
- 资助金额:
$ 38.91万 - 项目类别:
Mitochondrial dysfunction, oxidative stress, and surgical acute kidney injury
线粒体功能障碍、氧化应激和手术急性肾损伤
- 批准号:
9262049 - 财政年份:2012
- 资助金额:
$ 38.91万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 38.91万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 38.91万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 38.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 38.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 38.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)